Wellington Management

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026

Wellington Management is an investment manager with a private-investing platform spanning venture capital, growth and private debt, informed by its public-market research.

Its equity strategies include early-stage venture, private biotech, climate growth and late-stage growth. These teams address different development needs, from scientific breakthroughs and medical demand to scaling industrial systems and preparing for public markets.

A Value Creation Team connects portfolio companies with Wellington’s public- and private-market specialists from seed through IPO. The wider platform also provides growth lending, giving some businesses a debt-financing route alongside equity capital.

Sources
Rounds participated in
4
Confirmed lead rounds
—
4 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$457.5M
4 disclosed · full round size, not this investor’s share

By stage

Series A3
Series B1

By primary sector

Biotech4

By country

United States3
United Kingdom1

Rounds

4 in this selection
Crystalys Therapeutics

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B
Role not disclosed
RQ Bio

Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients

$115MSeries A
Role not disclosed